The investigation focused principally on two important hereditary syndromes: hereditary breast and ovarian cancer associated with germline pathogenic variants in BRCA1, and Lynch syndrome, which arises from inherited defects in DNA mismatch-repair genes. Germline variants are present in virtually every cell of the body, meaning that their biological effects can extend beyond the tissues in which tumors eventually develop. In BRCA1-associated disease, impaired repair of DNA double-strand breaks can increase genomic instability. Lynch syndrome, by contrast, is linked to faulty correction of replication errors, producing mismatch-repair deficiency and a high burden of mutations. Both settings can generate abnormal cells that immune surveillance mechanisms may recognize and eliminate before they progress into invasive cancer.

To investigate how these inherited risks intersect with immunity, the researchers combined three complementary technologies. Single-cell transcriptomics measured gene-expression programs in individual immune cells, allowing the team to distinguish subtle functional states that can be hidden when millions of cells are analyzed together. Multiparametric mass cytometry used metal-tagged antibodies and time-of-flight mass spectrometry to identify numerous proteins on and inside immune cells simultaneously, enabling detailed classification of lymphocyte and myeloid-cell populations. Cytokine profiling provided a biochemical readout of soluble immune signals circulating in blood. Together, these methods offered a multidimensional picture of immune-cell abundance, activation, differentiation, and communication in people with and without hereditary cancer risk.

One of the clearest observations was a reduction in the abundance of peripheral B cells in both women with BRCA1 germline pathogenic variants who had breast cancer and individuals with Lynch syndrome. The B-cell compartment also displayed a more differentiated phenotype. B cells are best known for producing antibodies, but they also present antigens to T cells, organize immune memory, and release regulatory molecules that influence inflammation. Their maturation proceeds through several stages, from naïve cells that have not yet encountered their target antigen to memory and antibody-secreting populations. A shift toward more differentiated states, together with lower overall abundance, may therefore reflect altered immune experience or regulation rather than a simple loss of immune function. The study does not show whether these changes are harmful, protective, or consequences of other biological processes.

The immune profile was especially notable among cancer-free women carrying BRCA1 pathogenic variants. Although these participants had no manifest cancer at the time of assessment, multiple immune-cell lineages showed an activated phenotype resembling that observed in patients with established disease. Activation can involve increased expression of antigen-presentation molecules, co-stimulatory proteins, inflammatory receptors, or cytotoxicity-associated markers. In practical terms, the result suggests that the immune system may be responding to persistent cellular stress, altered tissue signals, or the continual emergence and removal of abnormal cells in individuals with inherited susceptibility. This interpretation remains provisional: an activated peripheral immune profile is not equivalent to a tumor-specific response, and it should not be treated as evidence that cancer is present or imminent.

Lynch syndrome revealed a different pattern. In this group, B-cell phenotypes showed the largest changes associated with cancer eradication, indicating that the immune system’s circulating B-cell landscape may be particularly sensitive to the presence or removal of Lynch-associated tumors. The researchers also detected increased levels of interleukin-6, or IL-6, in presymptomatic individuals with Lynch syndrome. IL-6 is a multifunctional cytokine involved in acute and chronic inflammation, B-cell maturation, hematopoiesis, and communication between immune and nonimmune tissues. Persistently elevated IL-6 has been reported in several inflammatory and malignant conditions, but its presence in people without diagnosed cancer should be interpreted cautiously. The finding may reflect a syndrome-associated immune state, yet it requires validation in larger longitudinal cohorts before it can be considered a risk marker.

The contrast between the two syndromes is scientifically important because it argues against a single, universal immune signature of hereditary cancer predisposition. BRCA1 carriers appeared to show broad activation across several immune lineages even before disease became clinically evident, whereas Lynch syndrome was characterized more strongly by changes in B-cell states and systemic IL-6 elevation. These differences may arise from the distinct molecular defects underlying the syndromes, the tissues most vulnerable to transformation, the types of abnormal antigens generated, or the immune consequences of previous cancers and treatments. The study’s use of single-cell and high-dimensional protein measurements allowed the researchers to detect this biological complexity rather than reducing immunity to a single white-blood-cell count or inflammatory marker.

The findings also have potential implications for cancer interception, an emerging field focused on preventing malignancy or detecting it at its earliest stages. If immune alterations can be confirmed as stable, syndrome-specific, and predictive, they might eventually be used alongside genetic testing, imaging, endoscopic surveillance, and clinical history to refine individual risk assessments. They could also help identify biological pathways that are susceptible to intervention. The study points toward possible relevance for immune-checkpoint inhibitors, drugs that release inhibitory signals on T cells and are already important in mismatch-repair-deficient cancers. However, the researchers do not present evidence that immune therapy should be given to cancer-free carriers, and preventive treatment would require rigorous trials because immune activation can produce serious toxicity without providing benefit.

Several limitations place the results in context. The research captures immune features at one point in time, so it cannot determine how these profiles evolve before cancer, during tumor formation, after treatment, or over long-term surveillance. The participants also represent specific hereditary syndromes and clinical groups, meaning that the findings should not automatically be generalized to every inherited cancer-risk gene. Immune measurements can be influenced by age, sex, infection, medication, previous cancer, surgery, hormonal status, and other environmental factors. Even highly detailed molecular signatures may be difficult to translate into routine clinical testing unless they demonstrate reproducibility and clear predictive value. Future prospective studies following unaffected carriers over time will be essential to determine whether the observed immune states identify individuals at greater risk or instead reflect protective surveillance.

For now, the study provides evidence that hereditary cancer predisposition is accompanied by systemic immunological changes that can be detected in the bloodstream, including in people who appear clinically healthy. Its central message is not that an activated immune profile diagnoses cancer, but that inherited susceptibility and immune biology are closely connected. By mapping these connections across B cells, T cells, myeloid populations, and circulating cytokines, the researchers have created a foundation for investigating how the body recognizes and controls precancerous cells. The long-term goal is a more individualized approach to prevention—one that combines inherited genetic information with dynamic measurements of immune function to identify the most appropriate surveillance and risk-reduction strategies for each person.

Subject of Research: Systemic immune activation and peripheral immune alterations in hereditary cancer predisposition syndromes, particularly BRCA1-associated hereditary breast and ovarian cancer syndrome and Lynch syndrome.

Article Title: Systemic immune activation in hereditary cancer predisposition syndromes: a cross-sectional study

Article References: Kelemen, I., Horti-Oravecz, K., Bozsik, A. et al. “Systemic immune activation in hereditary cancer predisposition syndromes: a cross-sectional study.” BMC Medicine (2026).

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05188-x

Keywords: Hereditary breast and ovarian cancer syndrome, BRCA1, Lynch syndrome, precancer immunity, peripheral immune phenotype, cancer immunosurveillance, immune-checkpoint inhibitors, mass cytometry, single-cell transcriptomics, cytokine profiling

Fanconi anemia is a hereditary DNA repair disorder that compromises bone marrow function and increases cancer risk, particularly in the head and neck region. The malignancies encountered in these patients are often locally advanced or metastatic, making surgical options either unfeasible or insufficient. Historically, effective anticancer treatments tailored for FA-associated HNSCC have remained elusive, with conventional regimens frequently leading to severe hematological toxicities and limited success. This clinical void has driven researchers to investigate molecular targets that could offer safer, more efficacious alternatives.

Preclinical studies highlighted a vital cancer vulnerability: FA-HNSCC tumors markedly overexpress the epidermal growth factor receptor (EGFR), a protein known to drive malignancy progression by promoting tumor cell proliferation and survival. Afatinib, an irreversible tyrosine kinase inhibitor, potently blocks EGFR signaling and has demonstrated significant antitumor activity in models of head and neck cancer. Encouragingly, cells derived from FA-HNSCC are exquisitely sensitive to afatinib, paving the way for its orphan drug designation by the European Medicines Agency in 2018.

The AFAN trial is designed as a single-arm, open-label study enrolling approximately 25 patients with unresectable, locally advanced, or metastatic HNSCC in the context of FA. Participants may be treatment-naïve or have experienced disease progression after prior systemic therapies, including immunotherapy, chemotherapy, or cetuximab. The stepwise dosing regimen begins at 20 mg daily, escalating cautiously to 40 mg daily contingent upon tolerability and absence of adverse events. This titration scheme reflects a careful balance between maximizing antitumor efficacy and minimizing toxicity in a vulnerable patient cohort.

Patient monitoring in the AFAN trial is rigorous and comprehensive. Tumor response will be assessed every 12 weeks via cross-sectional imaging, employing CT or MRI scans. This schedule ensures timely detection of disease progression or secondary primary tumors, conditions that are particularly relevant in FA patients due to their genomic instability. The trial’s primary endpoint focuses on objective response rate (ORR) after nine months of afatinib treatment based on RECIST v1.1 criteria, a standardized method for evaluating tumor burden changes in clinical trials.

Beyond ORR, secondary endpoints will shed light on multiple dimensions of treatment impact. These include disease control rate, duration of response, disease-free survival, overall survival, and patient-reported outcomes related to quality of life. Safety is also a critical focal point; given the inherent fragility of FA patients, careful documentation of adverse effects and treatment tolerability is essential to establish afatinib’s risk-benefit profile. Ancillary correlative studies embedded in the trial design promise to broaden understanding of biological mechanisms underpinning response or resistance.

The statistical framework underpinning the AFAN trial utilizes a Simon two-stage design, optimizing patient enrollment while controlling for false-positive outcomes. The study aims to detect a meaningful improvement in the nine-month objective response rate, hypothesizing an increase from a baseline rate of 20% to a more promising 40%. Should early results exceed predefined thresholds, the trial will proceed to full enrollment, ensuring robust data collection in this rare patient population.

Afatinib’s mechanism of action as an irreversible EGFR inhibitor differentiates it markedly from earlier generation agents like cetuximab. By covalently binding to EGFR and related receptor tyrosine kinases, afatinib effectively suppresses downstream signaling pathways responsible for cellular proliferation, survival, and metastasis. This dual targeting has been linked to improved efficacy in various squamous cell carcinoma models, suggesting a mechanistic rationale for its testing in FA-HNSCC, where EGFR dependence is pronounced.

The trial’s launch represents a collaborative effort across multiple specialized centers with expertise in rare genetic disorders and oncologic care. Coordinating complex patient monitoring, dose adjustments, and safety management in FA requires multidisciplinary expertise spanning hematology, oncology, radiology, and supportive care disciplines. This integration underscores the importance of precision medicine approaches in addressing the unique challenges posed by FA-associated cancers.

Clinicians and researchers alike recognize that the development of acceptable therapies for FA-HNSCC has profound implications beyond this rare population. Insights gained from the AFAN trial could illuminate vulnerabilities shared by other genetically unstable tumors, expanding therapeutic horizons and facilitating personalized treatment approaches. Moreover, the trial exemplifies how orphan drug designations and targeted drug development can accelerate clinical innovation for underserved groups.

Patient engagement will be pivotal throughout the AFAN trial, with careful documentation of their experiences informing both efficacy and tolerability assessments. Outcomes from patient-reported metrics will complement traditional clinical data, providing a holistic view of afatinib’s impact on daily functioning, symptom burden, and overall well-being. Such insights are critical to defining the therapy’s real-world applicability and guiding future supportive care strategies.

Safety considerations are paramount given both the genetic predisposition of FA patients and the potential toxicities associated with tyrosine kinase inhibitors. Dose modifications, including reductions and delays, are incorporated flexibly into the protocol to mitigate adverse events. Close hematologic monitoring aims to preempt complications, while allowing patients to remain on therapy as long as benefit is observed and toxicity is manageable. This cautious approach exemplifies modern oncology trials’ emphasis on balancing efficacy with quality of life.

If successful, this trial will validate afatinib as a viable treatment paradigm in a setting historically marked by limited options and poor outcomes. The AFAN study is not merely a testing ground for a drug, but a beacon of hope for patients and families confronting the dual burdens of a rare genetic disorder and aggressive cancer. The authors and participating centers eagerly anticipate that positive trial results will translate into new standards of care and regulatory approvals.

In conclusion, the initiation of the AFAN trial marks a pivotal moment in addressing the unmet clinical needs of FA patients battling head and neck squamous cell carcinoma. By harnessing targeted inhibition of EGFR through afatinib, this study aims to offer a more effective and safer therapeutic option for a highly vulnerable population. With thorough monitoring, a robust statistical design, and comprehensive endpoints, the trial is poised to generate crucial evidence that could transform clinical practice and expand therapeutic possibilities for rare cancer subsets.

All eyes in both the oncology community and patient advocacy groups are now focused on the progress of this innovative endeavor. As enrollment proceeds and data accumulates in the coming months, the trial’s outcomes may redefine paradigms for treating genetically predisposed cancers. The AFAN trial embodies hope, scientific rigor, and the spirit of personalized medicine, charting a course toward improved survival and quality of life for patients with Fanconi anemia and advanced head and neck cancer.

Subject of Research: Investigation of the safety and efficacy of afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma

Article Title: Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma

Article References:
Anguera, G., Gallego, O., Llobet, M. et al. Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma. BMC Cancer 25, 1374 (2025). https://doi.org/10.1186/s12885-025-14619-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14619-6